Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
APRE
Aprea Therapeutics
$1.74
Chart
$1.5 (+16.00%)
$2.33 (-25.32%)
$4.07 (-57.25%)
$4.41 (-60.54%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
APRE
Aprea Therapeutics
Current Price
$1.74
Login to view Aprea Therapeutics (APRE) recommendation from the last 90 days from financial news and social media.
Chart
$1.5 (+16.00%)
$2.33 (-25.32%)
$4.07 (-57.25%)
$4.41 (-60.54%)
APRE Latest Headlines
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update. ATRN-119 our ATR inhibitor exhibits early evidence of single agent anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trialThree patients in the 550 mg twice daily cohort in the ongoing ABOYA-119 clinical trial demonstrated tumor shrinkage of 7% 14% and 21%ACESOT-1051 the Phase 1 trial of WEE1 inhibitor APR-1051 continues to advance with
Wed May 14, 2025
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update. ATRN-119 our ATR inhibitor exhibits early evidence of single agent anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trialThree patients in the 550 mg twice daily cohort in the ongoing ABOYA-119 clinical trial demonstrated tumor shrinkage of 7% 14% and 21%ACESOT-1051 the Phase 1 trial of WEE1 inhibitor APR-1051 continues to advance with
Wed May 14, 2025
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update. ATRN-119 our ATR inhibitor exhibits early evidence of single agent anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trialThree patients in the 550 mg twice daily cohort in the ongoing ABOYA-119 clinical trial demonstrated tumor shrinkage of 7% 14% and 21%ACESOT-1051 the Phase 1 trial of WEE1 inhibitor APR-1051 continues to advance with
Wed May 14, 2025
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update. ATRN-119 our ATR inhibitor exhibits early evidence of single agent anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trialThree patients in the 550 mg twice daily cohort in the ongoing ABOYA-119 clinical trial demonstrated tumor shrinkage of 7% 14% and 21%ACESOT-1051 the Phase 1 trial of WEE1 inhibitor APR-1051 continues to advance with
Wed May 14, 2025
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update. ATRN-119 our ATR inhibitor exhibits early evidence of single agent anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trialThree patients in the 550 mg twice daily cohort in the ongoing ABOYA-119 clinical trial demonstrated tumor shrinkage of 7% 14% and 21%ACESOT-1051 the Phase 1 trial of WEE1 inhibitor APR-1051 continues to advance with
Wed May 14, 2025
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update. ATRN-119 our ATR inhibitor exhibits early evidence of single agent anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trialThree patients in the 550 mg twice daily cohort in the ongoing ABOYA-119 clinical trial demonstrated tumor shrinkage of 7% 14% and 21%ACESOT-1051 the Phase 1 trial of WEE1 inhibitor APR-1051 continues to advance with
Wed May 14, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
APRE Stock trends
APRE Stock performance
APRE Stock analysis
APRE investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
